Viloxazine

Unassigned

New Medicines

Attention-deficit hyperactivity disorder (ADHD) in children aged 6 to 17 years

Information

New molecular entity
Supernus Pharmaceuticals
Supernus Pharmaceuticals

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Norepinephrine reuptake inhibitor with selective serotonin modulation activity
The prevalence of ADHD is estimated to be around 2.4% of children in the UK, more common in boys [2].
Attention-deficit hyperactivity disorder (ADHD) in children aged 6 to 17 years
Oral